We are live on ! Find out more
EIGR

Eiger BioPharmaceuticals, Inc.
EIGR

Delisted

EIGR was delisted on the 10th of April, 2024.

Back to rankings

0 hedge funds and large institutions have $0 invested in Eiger BioPharmaceuticals, Inc. in 2025 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $423K → $0 (-$423K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
–
Holders Change
-1
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
PBM
Propel Bio Management
California
-$423K
Name Holding Trade Value Shares
Change 		Change in
Stake
PBM
1
Propel Bio Management
California
– -$423K -146,381 Closed

EIGR Hedge Fund Activity: Q3 2025 in Review

0 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q3 2025, worth a combined $0 — down 100% from $423K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of EIGR and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Propel Bio Management, exiting entirely with an estimated $423K sold.

  • 0 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q3 2025, down from 1 in Q2 2025.
  • Funds reported $0 of Eiger BioPharmaceuticals, Inc. stock for Q3 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q3 2025 and 1 closed out, a net change of -1 holder.
  • The largest Eiger BioPharmaceuticals, Inc. seller in Q3 2025 was Propel Bio Management, an estimated $423K sold.

Based on aggregated 13F filings for Q3 2025.